In vivo selection during ofloxacin therapy of Escherichia coli with combined topoisomerase mutations that confer high resistance to ofloxacin but susceptibility to nalidixic acid

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 5, 2006, Pages 1054-1057

  Cattoir, Vincent ^a   Lesprit, Philippe ^a   Lascols, Christine ^a   Denamur, Erik ^b   Legrand, Patrick ^a   Soussy, Claude James ^a   Cambau, Emmanuelle ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM   (France)

Author keywords

DNA gyrase A; Fluoroquinolones; GyrA; ParC; Prostatitis; QRDRs

Indexed keywords

ANTIINFECTIVE AGENT; DNA TOPOISOMERASE; NALIDIXIC ACID; OFLOXACIN;

AGED; ARTICLE; BACTEREMIA; BLOOD; CASE REPORT; DRUG EFFECT; DRUG RESISTANCE; ENTEROBACTER INFECTION; ENZYMOLOGY; ESCHERICHIA COLI; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; DNA TOPOISOMERASES; DRUG RESISTANCE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; MALE; NALIDIXIC ACID; OFLOXACIN;

EID: 39049194832     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl361     Document Type: Article

References (13)

1. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005; 41 Suppl 2: 120-6.
2. Hopkins KL, Davies RH, Threlfall EJ. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: Recent developments. Int J Antimicrob Agents 2005; 25: 358-73.
3. Yu X, Susa M, Knabbe C et al. Development and validation of a diagnostic DNA microarray to detect quinolone-resistant Escherichia coli among clinical isolates. J Clin Microbiol 2004; 42: 4083-91.
4. Heisig P. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 1996; 40: 879-85.
5. Cambau E, Bordon F, Collatz E et al. Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid. Antimicrob Agents Chemother 1993; 37: 1247-52.
6. Gilbert DN, Kolhlepp SJ, Slama KA et al. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin and trovafloxacin. Antimicrob Agents Chemother 2001; 45: 883-92.
7. Denamur E, Bonacorsi S, Giraud A et al. High frequency of mutator strains among human uropathogenic Escherichia coli isolates. J Bacteriol 2002; 184: 605-9.
8. Weigel LM, Steward CD, Tenover FC. gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob Agents Chemother 1998; 42: 2661-7.
9. Hamouda A, Amyes SG. Novel gyrA and parC point mutations in two strains of Acinetobacter baumannii resistant to ciprofloxacin. J Antimicrob Chemother 2004; 54: 695-6.
10. Corbett KD, Berger JM. Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu Rev Biophys Biomol Struct 2004; 33: 95-118.
11. Truong QC, Nguyen Van JC, Shlaes D et al. A novel, double mutation in DNA gyrase A of Escherichia coli conferring resistance to quinolone antibiotics. Antimicrob Agents Chemother 1997; 41: 85-90.
12. Sindelar G, Zhao X, Liew A et al. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob Agents Chemother 2000; 44: 3337-43.
13. Komp Lindgren P, Marcusson LL, Sandvang D et al. Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. Antimicrob Agents Chemother 2005; 49: 2343-51.